Drug Discovery

The pharmaceutical industry is driven by the productivity of its R&D. Despite its success, the environment in which the pharmaceutical industry operates is becoming more competitive and the R&D process to bring a drug successfully to market remains challenging.

Drug development is a risky and expensive process and involves combining scientific excellence with a thorough understanding of the business environment. Industry leaders responsible for the world’s most successful pharmaceutical facilities will bring insight and examine the best strategies to ensure pharmaceutical companies can bring new drugs to market quicker and more efficiently.

Mapping out the future
Dr Allen Roses, Senior Vice President of Genetics Research at GSK, explains how by understanding our own genetic makeup, the possibility is there to create personalized drugs with greater efficacy and safety.
More >>

Renewing the Promise of Real-time PCR
During his four years of providing oligonucleotides and countless hours of designing and optimizing assays for his fellow scientists, as a certified vendor of real-time PCR primers and probes
More >>

Think small!
The role of nanotechnology in the future of medicine
More >>

How valuable is your protein?
The company’s breakthrough technology that accelerates the characterization, validation and commercialization of protein biomarkers.
More >>

A reagent system for gene expression profiling
A look at a proprietary cell-based signal amplification system for gene expression profiling.
More >>

A chance for pharmaceutical drug development
One of the biggest breakthroughs science has witnessed in the past decade is the discovery and broad application of gene silencing by RNA interference (RNAi). Since it was shown that double-stranded RNA molecules lead to digestion of homologous messenger RNAs (mRNAs) ? not only in plants or worms but also in animals and humans ? this technology has been widely used.
More >>

Walking the critical path
Collaboration is essential for success. We need to collectively embark on an aggressive, well-coordinated research to create a new generation of performance standards and predictive tools for drug development.
More >>

Ship of dreams
The National Human Genome Research Institute (NHGRI) was established in 1989 with the primary mission to lead the National Institutes of Health (NIH) contribution to the Human Genome Project (HGP).
More >>

Bridging the divide?
From the perspective of drug discovery scientists, knowing what related science is going on at different sites and how best collaboration may occur is key.
More >>

RNA Amplification – Preservation of a Precious Archive
Dr. Andrew I. Brooks Associate Professor of Environmental Medicine and Genetics
More >>

Trouble in the FDA pipeline?
Has the prodigious American drug development machine started to sputter? Peter Pitts, Director of the Center for Medicine in the Public Interest and a former Associate Commissioner of the FDA, investigates…
More >>

Launched: powerful substance search enhancements
Building on a decade of innovation, the new SciFinder 2006 advances SciFinder?s reputation as an essential information tool and ?part of the process? of chemical and pharmaceutical research.
More >>

RNA Amplification – Preservation of a Precious Archive
Dr. Andrew I. Brooks Associate Professor of Environmental Medicine and Genetics
More >>

Model behavior
Model behavior How ADMETRx is using data more effectively in drug discovery
More >>

SciFinder reaching more researchers at top pharmaceutical companies
Chemical Abstracts Service (CAS), a division of the American Chemical Society, has announced that its SciFinder® research tool is now in use at 48 of the top 50 pharmaceutical companies
More >>

Noninvasive Imaging in Drug Discovery and Development. Where to Begin
There has been much publicity and discussion concerning the role of noninvasive imaging techniques in drug discovery and development.
More >>

The ion age
Ion channels are of great interest to the pharmaceutical industry since they represent important therapeutic targets
More >>

GFC-Arrays: quick and reliable screening for regulator genes via high-throughput functional perturbation
Discovery of the key genes regulating a cellular process, a disease progression or a biological pathway has always been a major interest for most biomedical researchers.
More >>

Work better, faster, smarter
Christine McCue, Director of Marketing at Chemical Abstracts Service, explains how to accelerate research and discovery.
More >>

Targeting treatment
Personalized medicine: offering the promise of individualized therapy by incorporating molecular analyses.
More >>

Making the most of your knowledge
Optimizing scientific information management in pharmaceutical product development.
More >>

The hard cell: Genomics and the future of drug discovery
From the point of view of a biomedical scientist working to translate genetic discoveries into biological and therapeutic advances, scientific history can be divided into before genome and after genome.
More >>

RNAi goes genomic: target identification and validation with siRNAs
Recent genomics and proteomics initiatives, including microarray-based transcriptional profiling and analyses of protein interaction networks, have led to the identification of large numbers of potential drug targets.
More >>

The end of endpoint assays?
After two years of development, one company is introducing its extracellular flux (XF) technology, and is reinventing cell based assays in the process.
More >>

Use it or lose it! ? keeping control of your data
Drug discovery R&D places considerable and unique demands on the data generated
More >>

Speeding things up
Enabling data integration across the research organization is an effective way of boosting productivity for a pharmaceutical organization. Innovating affordably without sacrificing quality is a difficult balance to muster.
More >>